A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis SuppurativaThis study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 to 75
Critères de participation
Inclusion Criteria:
* Have a diagnosis of HS for at least 12 months.
* Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
* Have an (abscess plus inflammatory nodule) count of at least 5.
* Agree to use topical antiseptics daily.
* Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion Criteria:
* Have more than 20 draining fistulae.
* Have had surgical treatment for HS in the last 4 weeks before randomization.
* Have an active skin disease or condition, that could interfere with the assessment of HS.
* Have a current or recent acute, active infection.
* Are immunocompromised.
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Lieu de l'étude
Alberta Dermasurgery Centre
Alberta Dermasurgery CentreEdmonton, Alberta
Canada
Contactez l'équipe d'étude
DermEffects - Probity - PPDS
DermEffects - Probity - PPDSLondon, Ontario
Canada
Contactez l'équipe d'étude
Beacon Dermatology
Beacon DermatologyCalgary, Alberta
Canada
Contactez l'équipe d'étude
Simcoderm Medical & Surgical Dermatology Centre
Simcoderm Medical & Surgical Dermatology CentreBarrie, Ontario
Canada
Contactez l'équipe d'étude
Wiseman Dermatology Research Inc.
Wiseman Dermatology Research Inc.Winnipeg, Manitoba
Canada
Contactez l'équipe d'étude
Center de Recherche St Louis
Center de Recherche St LouisQuebec City, Quebec
Canada
Contactez l'équipe d'étude
Brunswick Dermatology Center
Brunswick Dermatology CenterFredericton, New Brunswick
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Eli Lilly and Company
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT06046729